These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36330519)

  • 1. Evolving understanding of antibody-dependent enhancement (ADE) of SARS-CoV-2.
    Yang Y; Xu F
    Front Immunol; 2022; 13():1008285. PubMed ID: 36330519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.
    Okuya K; Hattori T; Saito T; Takadate Y; Sasaki M; Furuyama W; Marzi A; Ohiro Y; Konno S; Hattori T; Takada A
    Microbiol Spectr; 2022 Apr; 10(2):e0155321. PubMed ID: 35319248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages.
    Maemura T; Kuroda M; Armbrust T; Yamayoshi S; Halfmann PJ; Kawaoka Y
    mBio; 2021 Oct; 12(5):e0198721. PubMed ID: 34579572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Dependent Enhancement with a Focus on SARS-CoV-2 and Anti-Glycan Antibodies.
    Ziganshina MM; Shilova NV; Khalturina EO; Dolgushina NV; V Borisevich S; Yarotskaya EL; Bovin NV; Sukhikh GT
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theoretical Explanation for the Rarity of Antibody-Dependent Enhancement of Infection (ADE) in COVID-19.
    Boldova AE; Korobkin JD; Nechipurenko YD; Sveshnikova AN
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Antibodies in the Treatment of SARS-CoV-2 Virus Infection, and Evaluating Their Contribution to Antibody-Dependent Enhancement of Infection.
    Farouq MAH; Acevedo R; Ferro VA; Mulheran PA; Al Qaraghuli MM
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.
    Wang YT; Allen RD; Kim K; Shafee N; Gonzalez AJ; Nguyen MN; Valentine KM; Cao X; Lu L; Pai CI; Johnson S; Kerwin L; Zhou H; Zhang Y; Shresta S
    Antiviral Res; 2021 Nov; 195():105185. PubMed ID: 34634289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction.
    Wang S; Wang J; Yu X; Jiang W; Chen S; Wang R; Wang M; Jiao S; Yang Y; Wang W; Chen H; Chen B; Gu C; Liu C; Wang A; Wang M; Li G; Guo C; Liu D; Zhang J; Zhang M; Wang L; Gui X
    Commun Biol; 2022 Mar; 5(1):262. PubMed ID: 35332252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Dependent Enhancement of SARS-CoV-2 Infection of Human Immune Cells: In Vitro Assessment Provides Insight in COVID-19 Pathogenesis.
    Shen XR; Li Q; Li HL; Wang X; Wang Q; Zheng XS; Geng R; Zhang YL; Li B; Jiang RD; Liu MQ; Zhu Y; Zhang W; Yang XL; Peng K; Zhou P
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
    Arvin AM; Fink K; Schmid MA; Cathcart A; Spreafico R; Havenar-Daughton C; Lanzavecchia A; Corti D; Virgin HW
    Nature; 2020 Aug; 584(7821):353-363. PubMed ID: 32659783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.
    Fierz W; Walz B
    Front Immunol; 2020; 11():1120. PubMed ID: 32582200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?
    Zanella I; Degli Antoni M; Marchese V; Castelli F; Quiros-Roldan E
    Int Immunopharmacol; 2022 Sep; 110():108943. PubMed ID: 35753123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Dependent Enhancement of SARS-CoV-2 Infection in the Era of Rapid Vaccine Development.
    Al Dossary R
    Med Arch; 2022 Oct; 76(5):383-386. PubMed ID: 36545460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
    Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
    mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.
    Ulrich H; Pillat MM; Tárnok A
    Cytometry A; 2020 Jul; 97(7):662-667. PubMed ID: 32506725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19.
    Karthik K; Senthilkumar TMA; Udhayavel S; Raj GD
    Hum Vaccin Immunother; 2020 Dec; 16(12):3055-3060. PubMed ID: 32845733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody dependent enhancement: Unavoidable problems in vaccine development.
    Xu L; Ma Z; Li Y; Pang Z; Xiao S
    Adv Immunol; 2021; 151():99-133. PubMed ID: 34656289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis.
    Thomas S; Smatti MK; Ouhtit A; Cyprian FS; Almaslamani MA; Thani AA; Yassine HM
    Mol Immunol; 2022 Dec; 152():172-182. PubMed ID: 36371813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Challenges of Vaccine Development Against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector].
    Zaichuk TA; Nechipurenko YD; Adzhubey AA; Onikienko SB; Chereshnev VA; Zainutdinov SS; Kochneva GV; Netesov SV; Matveeva OV
    Mol Biol (Mosk); 2020; 54(6):922-938. PubMed ID: 33276356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.
    Coish JM; MacNeil AJ
    Microbes Infect; 2020 Oct; 22(9):405-406. PubMed ID: 32590062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.